Establishing an Insulin-Resistance C2C12 Cell Model: A Systematic Review

 

Rita Rakhmawati1,5, Mae Sri Hartati Wahyuningsih2,4*, Arko Jatmiko Wicaksono2,4,

Mustofa Mustofa2, Ahmad Hamim Sadewa3

1Department of Medicine and Health Science Doctorate Program, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.

2Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.

3Department of Biochemistry, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.

4Center for Herbal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.

5Department of Pharmacy, Faculty of Mathematics and Natural Sciences,

Universitas Sebelas Maret, Surakarta, Indonesia.

*Corresponding Author E-mail: maeshw@ugm.ac.id

 

ABSTRACT:

Insulin resistance is one of the main risk factors for the development of diabetes mellitus. The search for natural ingredient-based drugs for antidiabetic treatment is widely carried out through experimental evidence in the laboratory. An in vitro model has advantages in easily maintaining and replicating. It is an appropriate choice for studying insulin resistance. The critical point in conducting insulin experiments in the early stages is to make the skeletal muscle C2C12 myotube form into insulin-resistant cells. For this reason, suitable types of insulin resistance inducers, effective concentrations, and administered inducer methods need to be discussed. This systematic review provides an overview of types of insulin resistance inducers in the C2C12 in vitro method, the effective concentrations in the molecular study of insulin resistance, and the technique administered by the inducer. Methods: The PubMed and Scopus databases were searched from 2012–2022. Results: Palmitic acid is one of the popular insulin resistance inducers. Concentrations of 0.20-0.75 mM palmitic acid are sufficient to cause insulin resistance. Inducing methods were administered simultaneously or in phases, together with the compound. The difference in the addition of inducers in forming the C2C12 cell model of insulin resistance is related to the research objectives for preventive/protective or curative purposes. The methods were successfully reported in establishing an insulin-resistant C2C12 cell model. 

 

KEYWORDS: Antidiabetic, C2C12, In vitro, Insulin resistance, Palmitic acid.

 

 


 

INTRODUCTION:

A significant concern to global health is the rise of diabetes mellitus (DM), and its complications are a severe problem for global health. Insulin resistance is the main cause of type 2 diabetes mellitus (T2DM), and it is linked to obesity and metabolic syndrome1. Insulin resistance is a major contributing factor to the development of T2DM. A decreased tissue response to insulin stimulation defines insulin resistance. The number of people with DM continues to rise worldwide. Diabetes mellitus currently affects 9.3% (463 million) of the world's population, and by 2030, By 2045, it is estimated to reach 10.9% (700 million) and 10.2% (578 million)2, 3.

 

The number of therapeutic alternatives to treat T2DM is increasing and now about 60 medications have been approved by the FDA, and 100 other antidiabetic medications are presently undergoing clinical trials for evaluation4. Biguanides, Sulfonylureas, Thiazolidinediones, Meglitinide, Pioglitazone, and Metformin are examples of medications currently available for the treatment of hyperglycemia in diabetes5. However, the current oral hypoglycaemic drugs used in clinical practice display certain patterns of major side effects and interactions with other drugs6,7. Besides modern medication, traditional antidiabetic plants are regarded as valuable sources for the development of novel oral hypoglycemic drugs. In the literature, over 800 plant species with potential hypoglycemic activity have been reported8,9,6.  However, before being introduced to the modern therapy system, in vitro and in vivo testing is needed. The search for natural ingredient-based DM treatments requires laboratory experiments, it needs animal models. Since the ethical handling of animals is as important as the well-being of humans, an in vitro model is suitable for investigating insulin resistance's cellular and molecular processes10. Appropriate application of the 3 Rs (reduction, refinement, and replacement) is required when using animals in experiments, and more study needs to be conducted in this area11,12. Thus, an in vitro model has advantages such as being easy to perform, reproducible, and avoiding tissue crosstalk13. Therefore, an in vitro model is a viable and appropriate choice to investigate14. Researching the anti-diabetic effects of drugs through in vitro cell line models could help the understanding of molecular mechanisms.

 

In the last few decades, a large number of cell lines have been found for in vitro research on diabetes mellitus such as isolated pancreatic β cells, insulin-secreting cell lines (HIT, MIN6, INS-1, RIN and beta-TC cells), HIT-T15 hamster pancreatic beta cells, 3T3 -L1 adipocytes, L6, C2C12, mesenchymal stem cell line, hepatic cell lines, BMS2, HEPG2, BC3H–112,15. A popular cell culture model for studying skeletal muscle is the C2C12 cell line. This cell line can facilitate investigating the mechanisms underlying insulin resistance. The body's largest organ in terms of mass is the skeletal muscle. It controls glucose homeostasis and clears the blood of 80% of postprandial glucose. Skeletal muscle is a principal target tissue for insulin action and a significant tissue for blood glucose utilization. Insulin primarily facilitates glucose uptake and metabolism. Insulin enhances skeletal muscle C2C12 glucose uptake by increasing the number of functional glucose transport molecules (GLUT-4) across the plasma membrane16. However, insulin-resistant states result in much lower insulin-stimulated glucose absorption in skeletal muscle.

 

To establish an in vitro insulin resistance model, various inducer exposures can be employed. The inducers are chronic insulin exposure17,18, dexamethasone (dex)19,20,21, a mixture of high glucose and high insulin (hyperinsulinemia)22, pro-inflammatory cytokines (TNF-α)23,24, free fatty acid/FFA25, IL-1β, (IL-6), numerous chemokines (Il1b, IL-6, Tnf, Mcp1)26 and adipocytokines27, adipokines28, hypoxia29, among others. However, the critical point in conducting insulin experiments is to make C2C12 myotubes form into insulin-resistant cells. For this reason, appropriate types of insulin resistance inducers and effective concentrations need to be discussed. An overview of the several types of insulin resistance inducers in the C2C12 in vitro method, as well as their concentrations in the molecular research of insulin resistance, induction time, and the administration of inducers, is described in this systematic review.

 

MATERIALS AND METHODS:

Guidelines and Study Search:

This systematic review used the PRISMA guidelines. The PubMed and Scopus databases were used to perform the literature search with keywords (“extract”) OR (“plant extracts”) OR (“compound”) AND (“insulin resistance”) OR (“insulin sensitivity”) AND (“molecular mechanism”) AND “(diabetes”) AND (“C2C12”) OR (“skeletal muscle"). Original papers (published from 2012-2022) were included in our systematic review.

 

Study filtering and extraction of data:

The results of the literature search were examined by two researchers. A third author was consulted in cases of disputed results to attain a consensus. Initially, all the titles of the literature were examined, and literature that met the criteria conducted subsequent abstract screening using Rayyan.ai (https://www.rayyan.ai/). The full texts that met the requirements were subjected to additional screening. In this investigation, only papers fulfilling the required standards were taken into consideration. The inclusion criteria were: (1) An English-language research article published between 2012 and 2022; (2) The work should focus on the study of insulin resistance and molecular mechanisms in C2C12 cells, specifically involving extracts or compounds derived from plants. The exclusion criteria encompassed articles that (1) were not available in the full version. (2) the presence of article duplication. Figure 1 depicts the steps of literature filtering and review.

 

We identified articles related to establishing an insulin-resistance model using C2C12 cells from the databases mentioned above. Furthermore, the papers were then divided into three categories: (1) induction time; (2) types and concentrations of inducers; and (3) administered time of inducers.

 

 

Figure 1. PRISMA flow diagram of systemic review search from 2012 to 2022.

 

RESULTS AND DISCUSSION:

Types and concentration of inducers of in vitro insulin-resistance models: One of the inducers of insulin resistance is palmitic acid (PA). Making in vitro models of insulin resistance in cell lines by inducer exposure is becoming more common13. Our review showed that 84% of researchers study insulin resistance using PA, and the remaining is TNF-α (Table 1). Free fatty acid, especially PA, is administered in most in vitro models to induce insulin resistance (IR). PA can induce insulin resistance to interfere with glucose absorption in C2C12 cells30. High plasma FFA levels have been associated with insulin resistance. It has been proposed that FFA reduces insulin sensitivity31 and inhibits insulin signaling32, resulting in insulin resistance.

 

Besides that, insulin resistance has been linked to inflammatory factors such as TNF-α. According to Lee et al.30, TNF-α inhibits the phosphorylation of both IRS and IR, increases the phosphorylation of IRS serine/threonine, increases the phosphorylation of tyrosine protein (Tyr) phosphatase 1B (PTP1B), and inhibits the insulin-stimulated glucose transporter (GLUT). These mechanisms result in a decrease in the expression of insulin receptors and insulin receptor substrate. TNF-α increases the formation of ceramide and diacylglycerol (DAG), which contributes to the development of insulin resistance in skeletal muscle33,34,35.

 

An in vitro insulin-resistance model can also be employed with various inducer concentrations36. Numerous investigations have shown that a 0.2-0.75 mM PA concentration is adequate to induce insulin resistance in a range of cell lines over 16–24 hours. However, some research revealed that PA significantly reduced the viability of cell lines. Moreover, PA significantly reduced the viability of C2C12 cell lines. Another preliminary study showed that cell viability was drastically reduced at a concentration of PA ≥ 0.25 mM, and approximately 61% of the C2C12 cells died when treated with 1 mM PA37. It has been noted that a high dose of PA (0.75 mM) leads to insulin resistance and is commonly utilized38-43. Another study examining PA-induced insulin resistance used PA at 200-250 μM since this concentration is comparable to that in the plasma of obese diabetes patients and does not induce toxicity to human neuroblastoma cells44.

 

To ascertain the role of APS (Astragalus polysaccharide) in PA-induced insulin resistance, two PA concentrations were used to incubate C2C12 myotubes (0.25 mM and 0.5 mM) with insulin (100 nM) and measure glucose uptake45. Giving 0.5 mM PA for 12 hours instead of 0.25 mM PA reduced the stimulatory effect of insulin on glucose uptake by 32%. The recovery of PA-reduced glucose uptake was dose-dependent. According to other research, PA did not exhibit cytotoxicity at 0.125 to 0.5 mM concentrations. However, cytotoxicity was seen at 1.0 mM, which led to a 7.29% (p < 0.05) decrease in cellular activity in contrast to the control (0 mM)46.

 

Another study examined the effect of PA concentrations on HepG2. Liu et al.47 assessed HepG2 cell survival at varying doses of PA of 0.125 mM to 2 mM. The result showed that after 24 hours, cell growth was less inhibited by low concentrations of 0.05–0.125 mM, but cell viability dramatically decreased at 0.25–2 mM. Low PA concentrations have minimal effect on cell viability, around 1.054%. It was found that utilizing HepG2 cells stimulated by PA, a low concentration of PA produced better outcomes in establishing an insulin-resistance model47.

 

Induction Time of Inducers: At different concentrations, the viability of cells significantly diminished across the induction period (24, 48, and 72 hours)47. Cell viability dramatically dropped at 0.25 mM–2 mM concentrations, but cells at low concentrations of 0.05 mM–0.125 mM showed less cell growth inhibition. The result showed that a reliable and stable insulin resistance model had been established. It was advised that the inducer be used for 24 hours during induction. It has been suggested that the enhancement of IRS-1 serine phosphorylation occurs when skeletal muscle cells are incubated with saturated fatty acids, which causes failure of glucose absorption. Alkhateeb et al.48 demonstrated that two different mechanisms induce insulin resistance carried on by PA. During the early period (6 hours), there is a reduction in GLUT4 translocation due to intramuscular ceramide and DAG accumulation. Thus, after exposure to PA for 12 and 18 hours, there is a noticeable decrease in GLUT4's intrinsic activity. Glucose transport driven by insulin was progressively reduced after 6 hours (~33%), 12 hours (~66%), and 18 hours (~89%). The decreased intrinsic activity of GLUT4 rather than the impaired GLUT4 translocation was the primary cause of the significant inhibition of insulin-stimulated glucose transport. The study by Nguyen et al.49 examined the potential concentrations- and time-dependent correlation between the expressions of IRS-1 and PA treatment (0.125–0.5 mM concentrations over 6–18 h) in hepatocytes. Numerous studies have connected the emergence of insulin resistance to low levels of IRS-1 protein. The findings showed that at a PA concentration of 0.5 mM, the levels of IRS-1 expression dramatically dropped with longer incubation times (6–18 hours). In line with the earlier research, a 16-hour PA administration reduced cellular activity in a manner that was dose-dependent46. Only Kim et al.,50 reported establishing insulin resistance in cultured C2C12 myotubes by administering PA for six hours, even though most of them incubated cell lines for at least 16 hours.

 

Administered time of inducers:

The two approaches for performing the insulin resistance method are as follows: the first involves giving the compound and inducers simultaneously. Thus, second, the compound is given in phases. There were two categories: adding the compound followed by an inducer and adding the inducer followed by the compound.

 

The difference in the addition of inducers in forming the C2C12 cell model of insulin resistance is likely related to the research purposes. The first approach is adding a compound with an inducer30,56,58 (Table 2). This model describes C2C12 cells that have not been in a state of insulin resistance. This treatment seems related to preventive/protective action, adding the compound seems to protect cells from PA-induced cytotoxicity.

 

Furthermore, the compound is administered gradually by adding the compound followed by the inducer, as seen in Table 3. The pretreatment also relates to preventive/protective action. Using this technique, a different study evaluated the compound's ability to protect C2C12 myotubes that had been damaged by PA. Pretreatment with the compound could protect cells from PA-induced cytotoxicity. Other research revealed that Hispidin pretreatment (from 1 to 100 μM) for 8 hours inhibited PA-induced cell death in C2C12 myotubes59. Hispidin is a phenolic compound obtained from a medicinal mushroom, Phellinus linteus. The study demonstrated that an 8-hour pretreatment with hispidin improved the viability of C2C12 myotubes in the face of oxidative stress induced by palmitate by inhibiting the production of intracellular reactive oxygen species (ROS). Apoptotic nuclear condensation induced by palmitate in C2C12 myotubes was also impeded by hispidin.

 

Table 1. Types and concentration of inducers for in vitro insulin resistance models

No.

Ref.

Methodology

 

 

 

Inducer

Inducer concentration

Duration

of induction (h)

1

51

TNF-α

10 ng/mL

24

2

30

TNF-α                      

20 ng/mL

20

3

52

TNF-α

20 ng/mL

24

4

45

(PA)

0,25 and 0,5 mM

12

5

46

(PA)

0,5 mM

16

6

53

(PA)

0,5 mM

16

7

54

(PA)

0,5 mmol/L

18

8

50

(PA)

0,5 mM

6

9

3

(PA)

0,5 mM

24

10

38

(PA)

0,75 mM

16

11

42

(PA)

0,75 mM

16

12

55

(PA)

0,25 and 0,75 mM

24

13

43

(PA)

0,75 mM

16

14

39

(PA)

0,75 mM

24

15

40

(PA)

0,75 mM

16

16

41

(PA)

0,75 mM

16

17

56

(PA)

200 μM

16

18

57

(PA)

200 μM

24

19

58

(PA)

250 μM

24

(PA): Palmitic acid


 

Table 2. Administering compounds along with inducers.

References

Compound

Insulin resistance method

Findings

30

Monascin (MS)

TNF-α (20 ng/mL) and MS were applied to C2C12 cells simultaneously in serum-free DMEM for 6 hours.

MS increased insulin sensitivity by controlling PPAR-c and preventing JNK activation via the Akt pathway.

56

PMI-5011 (ethanolic extract from Artemisia dracunculus)

Cells were treated with PMI-5011 and 200 μM PA for 16 hours.

 

PMI-5011 promotes AMPK's Thr172-phosphorylation in skeletal muscle tissue and muscle cells.

58

Oleuropein 1, 10 dan 100 υM

(Eisai Food and Chemical Co., LTD.Tokyo, Japan)

For 24 hours, cells were simultaneously treated with Oleuropein and PA 250 μM.

Oleuropein may increase skeletal muscle's sensitivity to insulin by promoting GLUT4 translocation without requiring insulin signals.

Table 3. Administering compounds is given in phases by adding the compound followed by an inducer.

References

Compound

Insulin resistance method

Important findings

43

Astragaloside IV from Pharmagenesis, Inc. (Redwood City, CA, USA)

Cells were treated with Astragaloside 2 h + PA 0,5 mM for 16 h

Astragaloside IV inhibits PA-induced activation of the IKK/IκBα pathway and increases glucose transport in C2C12 myotubes via the IRS1/AKT pathway.

39

Celastrol (10, 20, 30, 40, 50 dan 60 nM), an isolated compound from Tripterygium wilfordii (Sigma)

 

Cells were treated with Celastrol for 16 h+ PA 0,75 mM for 24 h.

Celastrol-mediated protection against PA-mediated insulin resistance is linked to improved mitochondrial metabolic processes through PI3K-Akt signaling pathway activation.

40

Eburicoic Acid, from Antrodia camphorata (TRR) 5, 10, 25μg/mL

 

Cells were treated with TRR for 2h + PA 0,75 mM for 16 h.

TRR increases peripheral insulin sensitivity while lowering lipid and glucose levels.

41

10 M BPN (0,1 mol) a marine-derived PTP1B inhibitor

 

Cells were treated with BPN 1h + PA 0,75 mM for 16 h.

GLUT4, the glucose transporter, was translocated in insulin-resistant and normal C2C12 myotubes upon PTP1B suppression by BPN, improving glucose absorption.

50

10 dan 25 μM Chicoric acid (CA) (Sigma-Aldrich)

 

Cells were treated with CA for 24 h + 0,5 mM PA for 6 h.

Ca stimulates insulin sensitivity and reduces insulin resistance by improving mitochondrial function.

3

10Μm CYC31, a Natural Bromophenol PTP1B Inhibitor

 

Cells were treated with CYC31 for 1h + 0,5 mM PA for 24 h.

 

CYC31 administration significantly raised the mRNA expression of fatty acid binding protein 3 (FABP3) and carnitine palmitoyltransferase 1B (CPT-1B), which in turn reduced PA-induced insulin resistance.

57

Benzyl Isothiocyanate (BITC) 5 μM from Sigma-Aldrich (St. Louis, MO)

Cells were treated with BITC for 16 h+ 200 μM PA 24 h.

BITC significantly prevents obese type 2 diabetes by upregulating IRS-1/AKT/TBC1D1 signaling activity in muscle cells

 


Several studies demonstrated that pretreatment with the compound for 1-24 hours, followed by the inducer ≥16 hours, successfully assessed PA-induced insulin resistance3,39-41,43,60,57. According to the study, C2C12 cells were exposed to PA for 16 hours after two hours of treatment with the substance eburicoic acid (TRR)40. The result showed that PA significantly lowered the expression levels of membrane GLUT4, p-AMPK/t-AMPK, and p-Akt/t-Akt in insulin-resistant C2C12 myotube cells. It showed 10 and 25 µg/mL of TRR; both could prevent and reverse this drop. Another study pretreatment with compound astragaloside IV for 2 hours showed improving glucose absorption in C2C12 myotubes exposed to PA (p<0.05)43. Another study treated C2C12 with celastrol for 16 hours, followed by PA for 24 hours. It was found that when exposed to 40 nM celastrol, levels of intracellular ATP contents, MMP, and citrate synthase activity were considerably up-regulated at concentrations of celastrol ranging from 20 to 40 nM39. Another study showed that C2C12 myotubes were preincubated with BPN (a marine-derived PTP1B inhibitor) for 1 hour and incubated for PA for 16 hours. It revealed that the successful compound improved glucose absorption in insulin-resistant. Another study showed that C2C12 was treated with compound BITC for 16 hours, followed by 200 μM PA for 24 hours57. The result showed that compound BITC prevents obese T2DM by upregulating IRS-1/AKT/TBC1D1 signaling activity in C2C12.

 

Furthermore, treatment involving the addition of the inducer followed by the compound (Table 4) likely reflects a curative approach. In this method, C2C12 cells were first exposed to palmitic acid (PA) for approximately 12 to 24 hours to induce insulin resistance (IR)40,42,45,52,55,60. Subsequently, a compound was administered, and its potential to alleviate insulin resistance was evaluated.


 

Table 4. Administering compounds is given in phases by adding the inducer followed by the compound

References

Compound

Insulin resistance method

Important findings

45

Astragalus polysaccharide (APS) (Pharmagenesis, Inc., Redwood City, CA, USA).

C2C12 cells were treated with 0,25 and 0.5 mM PA for 12h + 0.2 mg/mL APS for 12 h.

 

- 12 hours of 0.5 mM PA treatment resulted in a 32% (p<0.05) reduction in insulin stimulation on glucose absorption. - In C2C12 myotubes, APS reduces insulin resistance brought on by PA by preventing the NF-κB pathway from being activated.

60

PTF

Cells were treated with 0.5 mM PA for 16 h + PTF (0.5 mg/ml) for 16 h.

 

- A 16-hour pre-treatment with PA (0.5 mM) decreased the amount of glucose absorbed by insulin-induced C2C12 myotubes by 63.69% (P<0.01).

- Through β-arrestin-2-mediated signaling, PTF improves insulin-induced glucose absorption in C2C12 myotubes.

38

OSPT and OSPL, Orange-Fleshed Sweet Potato (ARC, Roodeplaat, South Africa) (Ipomoea batatas)

Cells were treated with 0.75 mM PA for 16 h + OSPT and OSPL extract for 3 h.

 

-Insulin-resistant cells treated with extracts from OSPT and OSPL showed that malonaldehyde dramatically dropped, intracellular GSH increased (p < 0.05), and intracellular antioxidant status significantly improved.

42

Platycodon grandiflorum (PG) seeds and roots (Seoul,

Korea) and Hans Herb Yeongcheon, Korea)

Cells were treated with 0.75 mM PA for 16 h +

PGSE and PGRE (200 μg/mL) for 3 h.

In PA-treated C2C12 myotubes, GLUT4 translocation increased by 1.7 times in the plasma membrane.

55

Aronia melanocarpa anthocyanin extracts

(AMAE)

Cells were treated with 0.75 mM PA for 24 h, + AMAE (0, 10, 20, 40, 80, 160, and 320 μg/mL) for 24 h.

Administration of 40 μg/mL AMAE had the strongest effect on insulin action and glycogen production in C2C12 and IR HepG2 cells.

53

Alismatis Rhizoma Triterpenes (ART), ARTC (mixture)

Cells were treated with 0.5 mM PA for 16 h + ART for 16h

The expression of IR-associated genes linked to the AMPK/JNK and IRS-1/PI3K/AKT/GLUT4 signaling pathways was significantly influenced by ARTC treatment in C2C12 cells triggered by PA.

52

WSP (Ipomoea batatas L.) (Taiwan)

Cells were treated with TNF-α (20 ng/mL) for 24 h + SP extract (12.5–200 µg/mL).

 

Through the PI3K/Akt pathway, WSP-EA increased glucose absorption in C2C12 myotubes.

40

Icariin compound (an 8-prenyl derivative of kaempferol 3,7-O-diglucoside), isolated from the Epimedium genus

Cells were treated with 0,5 mM PA for 18 h + Icariin for 18 h.

Icariin reduces TXNIP levels and prevents ER stress, inhibiting insulin resistance via a proteasome-dependent mechanism.

 


Li et al.61 discovered that autophagic acid vesicles increased in quantity following PA treatment over the first 24 hours and diminished for the following 36 hours. This method tends to describe the actual DM condition because the cell line was in a state of insulin resistance before being treated with the compound. Even though there were differences in the type of inducer, inducer concentration, and methodologies used in research studies, the methods successfully established insulin resistance in the C2C12 model.

 

CONCLUSION:

Several researchers have successfully established skeletal muscle cell models of insulin resistance, with palmitic acid (PA) being one of the most commonly used inducers. PA concentrations ranging from 0.2 to 0.75 mM are generally sufficient to induce insulin resistance. Variations in the timing and method of PA administration in developing insulin-resistant C2C12 models are often tailored to specific research objectives, whether curative, preventive or protective.

 

CONFLICT OF INTEREST:

The authors declare no conflict of interest.

 

ACKNOWLEDGMENTS:

The authors thank the financial support from the project Rekognisi Tugas Akhir (RTA), Gadjah Mada University (Grant No: 5286/UN1.P1/PT.01.03/2024).

 

REFERENCES:

1.      Abdul-Ghani MA. DeFronzo RA. Pathogenesis of Insulin Resistance in Skeletal Muscle. Journal Biomed Biotechnology. 2010; 2010: 476279. doi: 10.1155/2010/476279.

2.      Saeedi P. Petersohn I. Salpea P. Malanda B. Karuranga S. Unwin N. Colagiuri S. Guariguata L. Motala AA. Ogurtsova K. Shaw J. E. Bright D.  Williams R et al. Global and Regional Diabetes Prevalence Estimates for 2019 And Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. 9th edition. Diabetes Research and Clinical Practice. 2019; 157: 107843. https://doi.org/10.1016/j.diabres.2019.107843.

3.      Luo J. Hou Y. Xie M. Ma W. Shi D. Jiang. B et al. CYC31. A Natural Bromophenol PTP1B Inhibitor Activates Insulin Signaling and Improves Long Chain Fatty Acid Oxidation in C2C12 Myotubes. Marine Drugs. 2020; 18(267): https://doi.org/10.3390/md18050267

4.      Dahlén, A. D., Dashi, G., Maslov, I., Attwood, M. M., Jonsson, J., Trukhan, V., and Schiöth, H. B. Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales. Frontiers in Pharmacology. 2022; 12, 1–16. https://doi.org/10.3389/fphar.2021.807548

5.      Sujatha Kumari, M., Kiran Babu, M., Sulthana, M. R., Srinivas, M., and Prasanthi, C. Diabetes mellitus: Present status and drug therapy updates. Research Journal of Pharmacy and Technology. 2014; 7(1), 84–94.

6.      Pandeya, S. N., Kumar, R., Kumar, A., and Pathak, A. K. Antidiabetics Review on Natural Products. Research Journal of Pharmacy and Technology. 2010; 3(2), 300–318.

7.      Keerthana, K., and Jothi, G.  Determination of In vitro antidiabetic potential of Aqueous and Ethanol extracts and isolated fraction of Zanthoxylum armatum DC stem bark. Research Journal of Pharmacy and Technology. 2020; 13(8), 3681. https://doi.org/10.5958/0974-360x.2020.00651.4

8.      Preethi, P. J. Review Article Herbal medicine for diabetes mellitus : A Review. Asian J. Pharm. Res. 2013'  3(2), 57–70.

9.      Devaliya, R., and Shirsat, M. A review on indigenous medicinal plants for diabetes mellitus. Research Journal of Pharmacy and Technology. 2017; 10(8), 2828–2836. https://doi.org/10.5958/0974-360X.2017.00499.1

10.   Keerthana, K., and Jothi, G.  Determination of in vitro antidiabetic potential of Aqueous and Ethanol extracts and isolated fraction of Zanthoxylum armatum DC stem bark. Research Journal of Pharmacy and Technology. 2020; 13(8), 3681. https://doi.org/10.5958/0974-360x.2020.00651.4

11.   Doke SK. Dhawale SC. Alternatives to Animal Testing: A Review. Saudi Pharmaceutical Journal. 2015; 23(3): 223–229. https://doi.org/10.1016/j.jsps.2013.11.002

12.   Antony, J., Satadal, D., Manisha, C., Peet Thomas, Victoria Jeyarani, and Choephel, T. In-vitro cell line models and assay methods to study the anti-diabetic activity. Research Journal of Pharmacy and Technology. 2019; 12(5); 2200–2206. https://doi.org/10.5958/0974-360X.2019.00367.6

13.   Yudhani R D. Sari Y. Nugrahaningsih DAA. Sholikhah EN. Rochmanti M. Purba AKR. Khotimah H. Nugrahenny D.  Mustofa M et al. In Vitro Insulin Resistance Model: A Recent Update. Journal of Obesity. 2023. https://doi.org/10.1155/2023/1964732

14.   Jakovljevic NK. Pavlovic K. Zujovic T. Kravic-Stevovic T. Jotic A. Markovic I Lalic NM et al.  In Vitro Models of Insulin Resistance: Mitochondrial Coupling is Differently Affected in Liver and Muscle Cells. Mitochondrion. 2021; 61: 165–173. https://doi.org/10.1016/j.mito.2021.10.001

15.   Wong, C. Y., Al-Salami, H., and Dass, C. R. C2C12 cell model: its role in understanding of insulin resistance at the molecular level and pharmaceutical development at the preclinical stage. Journal of Pharmacy and Pharmacology, 2020; 72(12), 1667–1693. https://doi.org/10.1111/jphp.13359

16.   Batra, S., Batra, N., Pareek, A., and Nagori, B. P. In vitro study of Cayratia trifolia (L.) domin on isolated rat hemidiaphragm by glucose uptake method. Research Journal of Pharmacy and Technology. 2012; 5(5), 691–693.

17.   Yang C. Aye CC. Li X. Diaz Ramos A. Zorzano A.  Mora S et al. Mitochondrial Dysfunction in Insulin Resistance: Differential Contributions of Chronic Insulin and Saturated Fatty Acid Exposure in Muscle Cells. Bioscience Reports. 2012; 32(5): 465–478. https://doi.org/10.1042/BSR20120034

18.   Thomson MJ. Williams MG.  Frost SC. Development of Insulin Resistance in 3T3-L1 Adipocytes. Journal of Biological Chemistry. 1997; 272(12): 7759–7764. https://doi.org/10.1074/jbc.272.12.7759

19.   Henriksen JE. Alford F. Ward GM. Beck-Nielsen H et al. Risk and Mechanism of Dexamethasone-Induced Deterioration of Glucose Tolerance in Non-Diabetic First-Degree Relatives of NIDDM Patients. Diabetologia. 1997; 40(12): 1439–1448. https://doi.org/10.1007/s001250050847

20.   Sakoda H. Ogihara T. Anai M. Funaki M. Inukai K. Katagiri H. Fukushima Y. Onishi Y. Ono H. Fujishiro M. Kikuchi M. Oka Y.  Asano T et al. Dexamethasone-Induced Insulin Resistance in 3T3-L1 Adipocytes is Due to Inhibition of Glucose Transport Rather than Insulin Signal Transduction. Diabetes. 2000; 49(10): 1700–1708. https://doi.org/10.2337/diabetes.49.10.1700

21.   Biradar, K. V, Patil, C. B., Chivde, B. V, Malipatil, M. H., and Sanjivkumar, D. Effect of Superoxide Dismutase Mimetic Tempol on Dexamethasone Induced Insulin Resistance- Role of Oxidative Stress. ABSTRACT : Research J. Pharmacology and Pharmacodynamics. 2011; 3(3), 134–137.

22.   Mariappan MM. Feliers D. Mummidi S. Choudhury GG.  Kasinath BS et al. High Glucose, High Insulin, and Their Combination Rapidly Induce Laminin-β1 Synthesis by Regulation of mRNA Translation in Renal Epithelial Cells. Diabetes. 2007; 56(2): 476–485. https://doi.org/10.2337/db05-1334

23.   Moller DE. Potential Role of TNF-α in the Pathogenesis of Insulin Resistance and Type 2 Diabetes. Trends in Endocrinology and Metabolism. 2000; 11(6): 212–217. https://doi.org/10.1016/S1043-2760(00)00272-1

24.   Miles PDG. Romeo OM. Higo K. Cohen A. Rafaat K.  Olefsky JM et al. TNF-α-Induced Insulin Resistance In Vivo And Its Prevention by Troglitazone. Diabetes. 1997; 46(11): 1678–1683. https://doi.org/10.2337/diab.46.11.1678

25.   Yang Q. Zhu Z. Wang L. Xia H. Mao J. Wu J. Kato K. Li H. Zhang J. Yamanaka K. An Y. The Protective Effect of Silk Fibroin on High Glucose-Induced Insulin Resistance in HepG2 Cells. Environmental Toxicology and Pharmacology. 2019; 69: 66-71. doi: 10.1016/j.etap.2019.04.001.

26.   de Luca C. Olefsky JM. Inflammation and Insulin Resistance. FEBS Letters. 2008; 582(1): 97–105. https://doi.org/10.1016/j.febslet.2007.11.057

27.   Pittas AG. Joseph NA.  Greenberg AS. Adipocytokines and Insulin Resistance. Journal of Clinical Endocrinology and Metabolism. 2004; 89(2): 447–452. https://doi.org/10.1210/jc.2003-031005

28.   Rabe K. Lehrke M. Parhofer KG.  Broedl UC et al. Adipokines and Insulin Resistance. Molecular Medicine. 2008; 14(11–12): 741–751. https://doi.org/10.2119/2008-00058.Rabe

29.   Sharma P. Sri Swetha Victoria V. Praneeth Kumar P. Karmakar S. Swetha M.  Reddy A et al. Cross-Talk Between Insulin Resistance and Nitrogen Species in Hypoxia Leads to Deterioration of Tissue and Homeostasis. International Immunopharmacology. 2023; 122(12): 110472. https://doi.org/10.1016/j.intimp.2023.110472

30.   Lee BH. Hsu WH. Liao. TH.  Pan TM et al. The Monascus Metabolite Monascin Against TNF-α-Induced Insulin Resistance via Suppressing PPAR-γ Phosphorylation in C2C12 Myotubes. Food and Chemical Toxicology. 2011; 49(10): 2609–2617. https://doi.org/10.1016/j.fct.2011.07.005

31.   Nursucihta S. Thai’in HA. Putri MD Utami DN.  Ghani AP et al. Antianemia Activity of Parkia speciosa hassk Seed Ethanolic Extract. Traditional Medicine Journal. 2014; 19(05); 49–54.

32.   Gong L. Zou Z. Huang L. Guo S. Xing D et al. Photobiomodulation Therapy Decreases Free Fatty Acid Generation and Release in Adipocytes to Ameliorate Insulin Resistance in Type 2 Diabetes. Cellular Signalling. 2020; 67: 109491. https://doi.org/10.1016/j.cellsig.2019.109491

33.   Li HB. Yang YRY. Mo ZJ. Ding Y.  Jiang WJ et al. Silibinin Improves Palmitate-Induced Insulin Resistance in C2C12 Myotubes by Attenuating IRS-1/PI3K/Akt Pathway Inhibition. Brazilian Journal of Medical and Biological Research.  2015; 48(5): 440–446. https://doi.org/10.1590/1414-431X20144238

34.   Schütze S. Berkovic D. Tomsing O. Unger C.  Krönke M. Tumor necrosis Factor Induces Rapid Production of 1′2′Diacylglycerol by a Phosphatidylcholine-Specific Phospholipase C. Journal of Experimental Medicine. 1991;  174(5): 975–988. https://doi.org/10.1084/jem.174.5.975

35.   Adams JM. Pratipanawatr T. Berria R. Wang E. DeFronzo RA. Sullards MC.  Mandarino LJ. Ceramide Content Is Increased in Skeletal Muscle from Obese Insulin-Resistant Humans. Diabetes. 2004; 53(1): 25–31. https://doi.org/10.2337/diabetes.53.1.25

36.   Malik SA. Acharya JD. Mehendale NK. Kamat SS. Ghaskadbi SS et al. Pterostilbene Reverses Palmitic Acid-Mediated Insulin Resistance in HepG2 Cells by Reducing Oxidative Stress and Triglyceride Accumulation. Free Radical Research. 2019; 53(7): 815–827. https://doi.org/10.1080/10715762.2019.1635252

37.   Park JM. Lee JS. Song JE. Sim YC. Ha SJ.  Hong EK et al. Cytoprotective Effect of Hispidin Against Palmitic Acid-Induced Lipotoxicity in C2C12 Myotubes. Molecules. 2015; 20(4): 5456–5467. https://doi.org/10.3390/molecules20045456

38.   Ayeleso TB. Ramachela K. Mukwevho E. Aqueous-Methanol Extracts of Orange-Fleshed Sweet Potato (Ipomoea batatas) Ameliorate Oxidative Stress and Modulate Type 2 Diabetes-Associated Genes in Insulin-Resistant C2C12 Cells. Molecules. 2018; 23(2058). https://doi.org/10.3390/molecules23082058

39.   Bakar MHA. Tan JS. Improvement of Mitochondrial Function by Celastrol in Palmitic Acid-Treated C2C12 Myotubes via Activation of the PI3K-Akt Signaling Pathway. Biomedicine and Pharmacotherapy. 2017; 93: 903–912. https://doi.org/10.1016/j.biopha.2017.07.021

40.   Lin CH. Kuo YH.  Shih CC. Eburicoic Acid: A Triterpenoid Compound from Antrodia camphorata Displays Antidiabetic and Antihyperlipidemic Effects in Palmitic Acid-Treated C2C12 Myotubes and High-Fat Diet-Fed Mice. International Journal of Molecular Sciences. 2017; 18(2314). https://doi.org/10.3390/ijms18112314

41.   Xu Q. Luo J. Wu N. Zhang R.  Shi D et al. BPN. A Marine-Derived PTP1B Inhibitor Activates Insulin Signaling and Improves Insulin Resistance in C2C12 Myotubes. International Journal of Biological Macromolecules. 2018; 106: 379–386. https://doi.org/10.1016/j.ijbiomac.2017.08.042

42.   Yoon HJ. Bang MH. Kim H.  Imm JY et al. Improvement of Palmitic Acid-Induced Insulin Resistance in C2C12 Skeletal Muscle Cells Using Platycodon grandiflorum Seed Extracts. Food Bioscience. 2018; 25(07): 61–67. https://doi.org/10.1016/j.fbio.2018.08.002

43.   Zhu R. Zheng J. Chen L. Gu B.  Huang S et al. Astragaloside IV Facilitates Glucose Transport in C2C12 Myotubes through the IRS1/AKT Pathway and Suppresses the Palmitic Acid-Induced Activation of the IKK/IB Pathway. International Journal of Molecular Medicine. 2016; 37(6): 1697–1705. https://doi.org/10.3892/ijmm.2016.2555

44.   Sánchez-Alegría K. Bastián-Eugenio CE. Vaca L. Arias C. Palmitic Acid Induces Insulin Resistance by a Mechanism Associated with Energy Metabolism and Calcium Entry In Neuronal Cells. Federation of American Societies for Experimental Biology Journal. 2021; 35(7). https://doi.org/10.1096/fj.202100243R

45.   Zhao M. Zhang ZF. Ding Y. Wang JB.  Li Y et al. Astragalus Polysaccharide Improves Palmitic Acid-Induced Insulin Resistance by Inhibiting PTP1B and NF-κB in C2C12 Myotubes. Molecules. 2012; 17(6): 7083–7092. https://doi.org/10.3390/molecules17067083

46.   Feng XT. Wang TZ. Leng J. Chen Y. Liu JB. Liu Y. Wang WJ et al. Palmitic Acid Contributes to Insulin Resistance Through Downregulation of the Src-Mediated Phosphorylation of Akt in C2C12 Myotubes. Bioscience. Biotechnology and Biochemistry. 2012; 76(7): 1356–1361. https://doi.org/10.1271/bbb.120107

47.   Liu L. Zhang X. Chen F. Hu J. Zeng B et al. The Establishment of the Insulin Resistance Model. BIO Web of Conferences. 2017; 8: 03005. https://doi.org/10.1051/bioconf/20170803005

48.   Alkhateeb H. Chabowski A. Glatz JFC. Luiken JFP. Bonen A et al. Two Phases of Palmitic Acid-Induced Insulin Resistance in Skeletal Muscle: Impaired GLUT4 Translocation is Followed by a Reduced GLUT4 Intrinsic Activity. American Journal of Physiology - Endocrinology and Metabolism. 2007; 293(3): 783–793. https://doi.org/10.1152/ajpendo.00685.2006

49.   Nguyen MT. Min KH. Lee W. MiR-183-5p Induced by Saturated Fatty Acids Hinders Insulin Signaling by Downregulating Irs-1 In Hepatocytes. International Journal Molecular Science. 2022; 23(6): 2979. doi: 10.3390/ijms23062979.

50.   Kim JS. Lee H. Jung CH. Lee SJ. Ha. TY.  Ahn J et al. 2018. Chicoric Acid Mitigates Impaired Insulin Sensitivity by Improving Mitochondrial Function. Bioscience. Biotechnology and Biochemistry. 82(7). 1197–1206. https://doi.org/10.1080/09168451.2018.1451742

51.   Dai X. Ding Y. Zhang Z. Cai X. Bao L.  Li Y et al. Quercetin But Not Quercitrin Ameliorates Tumor Necrosis Factor-Alpha-Induced Insulin Resistance in C2C12 Skeletal Muscle Cells. In Biological and Pharmaceutical Bulletin 2013; 36(5).

52.   Shyur LF. Varga V. Chen CM. Mu SC. Chang YC.  Li SC et al. Extract of white Sweet Potato Tuber Against TNF-α-induced Insulin Resistance by Activating the PI3K/Akt pathway in C2C12 Myotubes. Botanical Studies. 2021; 62(7). https://doi.org/10.1186/s40529-021-00315-8

53.   Jia XK. Huang JF. Huang XQ. Li XY. Huang MQ. Zhu HC. Li GP. Lan ML. Yu ZW. Xu W. Wu SS. et al. Alismatis Rhizoma Triterpenes Alleviate High-Fat Diet-Induced Insulin Resistance in the Skeletal Muscle of Mice. Evidence-Based Complementary and Alternative Medicine. 2021. https://doi.org/10.1155/2021/8857687

54.   Li M. Zhang Y. Cao Y. Zhang D. Liu L. Guo Y et al.  Wang C. Icariin ameliorates Palmitic Acid-Induced Insulin Resistance by Reducing Thioredoxin-Interacting Protein (TXNIP) and Suppressing ER Stress in C2C12 Myotubes. Frontiers in Pharmacology. 2018; 9(OCT). https://doi.org/10.3389/fphar.2018.01180

55.   Chen J. Zhu J. Meng X. Aronia melanocarpa Anthocyanin Extracts are an Effective Regulator Of Suppressor Of Cytokine Signaling 3-Dependent Insulin Resistance in HepG2 and C2C12 Cells. Journal of Functional Foods. 2020; 75(September): 104258. https://doi.org/10.1016/j.jff.2020.104258

56.   Vandanmagsar B. Yu Y. Simmler C. Dang TN. Kuhn P. Poulev A. Ribnicky DM. Pauli GF.  Floyd ZE et al. Bioactive Compounds from Artemisia dracunculus L. Activate AMPK Signaling in Skeletal Muscle. Biomedicine and Pharmacotherapy. 2021; 143(06). https://doi.org/10.1016/j.biopha.2021.112188

57.   Chuang WT. Yen CC. Huang CS. Chen HW.  Lii CK et al. Benzyl Isothiocyanate Ameliorates High-Fat Diet-Induced Hyperglycemia by Enhancing Nrf2-Dependent Antioxidant Defense-Mediated IRS-1/AKT/TBC1D1 Signaling and GLUT4 Expression in Skeletal Muscle. Journal of Agricultural and Food Chemistry. 2020; 68(51): 15228–15238. https://doi.org/10.1021/acs.jafc.0c06269

58.   Fujiwara Y. Tsukahara C. Ikeda N. Sone Y. Ishikawa T. Ichi I. Koike T. Aoki Y et al. Oleuropein Improves Insulin Resistance in Skeletal Muscle by Promoting The Translocation of GLUT4. Journal of Clinical Biochemistry and Nutrition. 2017; 61(3): 196–202. https://doi.org/10.3164/jcbn.166120

59.   Park JM. Lee JS. Song JE. Sim YC. Ha SJ. Hong EK. Cytoprotective Effect of Hispidin Against Palmitic Acid-Induced Lipotoxicity in C2C12 Myotubes. Molecules. 2015; 20(4): 5456–5467. https://doi.org/10.3390/molecules20045456

60.   Feng XT. Wang TZ. Chen Y. Liu JB. Liu Y. Wang WJ et al. Pollen typhae Total Flavone Improves Insulin-Induced Glucose Uptake Through the Β-Arrestin-2-Mediated Signaling In C2C12 Myotubes. International Journal of Molecular Medicine. 2012; 30(4): 914–922. https://doi.org/10.3892/ijmm.2012.1061

61.   Li S. Li H. Yang D. Yu X. Irwin DM. Niu G. Tan H. Excessive Autophagy Activation and Increased Apoptosis Are Associated with Palmitic Acid-Induced Cardiomyocyte Insulin Resistance. Journal of Diabetes Research. 2017. https://doi.org/10.1155/2017/2376893

 

 

 

 

 

Received on 18.01.2024      Revised on 07.10.2024

Accepted on 18.04.2025      Published on 01.10.2025

Available online from October 04, 2025

Research J. Pharmacy and Technology. 2025;18(10):5027-5034.

DOI: 10.52711/0974-360X.2025.00726

© RJPT All right reserved

 

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.